Form 8-K

0001193125-17-026529.txt : 20170201 0001193125-17-026529.hdr.sgml : 20170201 20170201060902 ACCESSION NUMBER: 0001193125-17-026529 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170119 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20170201 DATE AS OF CHANGE: 20170201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DAVITA INC. CENTRAL INDEX KEY: 0000927066 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 510354549 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14106 FILM NUMBER: 17563016 BUSINESS ADDRESS: STREET 1: 2000 16TH STREET CITY: DENVER STATE: CO ZIP: 80202 BUSINESS PHONE: 310-536-2668 MAIL ADDRESS: STREET 1: 2000 16TH STREET CITY: DENVER STATE: CO ZIP: 80202 FORMER COMPANY: FORMER CONFORMED NAME: DAVITA HEALTHCARE PARTNERS INC. DATE OF NAME CHANGE: 20121107 FORMER COMPANY: FORMER CONFORMED NAME: DAVITA INC DATE OF NAME CHANGE: 20001005 FORMER COMPANY: FORMER CONFORMED NAME: TOTAL RENAL CARE HOLDINGS INC DATE OF NAME CHANGE: 19950524 8-K 1 d338717d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 19, 2017

DAVITA INC.

(Exact name of registrant as specified in its charter)

Delaware

1-14106

No. 51-0354549

(State or other

jurisdiction of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2000 16^th Street

Denver, CO 80202

(Address of principal executive offices including Zip Code)

(303) 405-2100

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

❑	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)

❑	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

❑	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

❑	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13c-4)

Item 7.01 Regulation FD Disclosure

DaVita Inc. (the “Company”) had a lawsuit pending in the U.S. Court of Federal Claims against the federal government, which was originally filed in May 2011 and previously disclosed by the Company. The lawsuit related to the U.S. Department of Veterans Affairs (“VA”) underpayment of dialysis services the Company provided from 2005 through 2011 to patients pursuant to VA regulations. The Company and the government amicably reached a resolution of the Company’s claims for $538 million, which will be subject to taxes and consideration of non-controlling interests. This one time settlement is expected to be recognized in the financial statements that will be included in the Company’s Quarterly Report on Form 10-Q for the first quarter 2017.

The information contained in Item 7.01 of this Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


				DAVITA INC.

Date: January 31, 2017				/s/ Kathleen Waters
				Kathleen Waters
				Chief Legal Officer